EpiCept had a commercial presence at both the European Hematology Association earlier this year and at the American Society of Hematology meeting in December. The company intends to continue and expand upon these efforts in 2010 in conjunction with a European partner, as appropriate, to facilitate the commercial launch of Ceplene.